TheraGenetics closes L3 million financing

TheraGenetics, an emerging UK-based personalized medicine diagnostics company focused on central nervous system disorders, has announced the completion of a L3.0 million ($6.0 million) series A venture financing round. Swarraton Partners led the financing with participation from Tudor Capital, IP Venture Fund, IP Group venture capital fund which was raised in partnership with the European Investment Fund, and existing investor IP Group plc. As part of the transaction, Stephen Brooke, managing partner of Swarraton, has joined TheraGenetics' board of directors.

TheraGenetics has developed a series of proprietary technologies and methods in the field of personalized medicine, based on pharmacogenetics. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the development of the first pharmacogenetic test for response prediction in psychiatry. The company is building on that success and developing a portfolio of additional pharmacogenetic diagnostic tests.